You are here: Industry Insights > leukaemia

News List

CAR T therapy achieves high remission rate in acute lymphoblastic leukaemia trial europeanpharmaceuticalreview
June 18, 2021
Trial data shows 71 percent of adult B cell acute lymphoblastic leukaemia patients receiving Tecartus® autologous anti-CD19-transduced CD3+ cell infusion achieved complete remission.
Calquence Demonstrates Fewer Incidences of Atrial Fibrillation vs Ibrutinib in Patients with Leukaemia americanpharmaceuticalreview
June 09, 2021
Final results from the head-to-head ELEVATE-RR Phase III trial of AstraZeneca’s Calquence (acalabrutinib) demonstrated non-inferior progression-free survival (PFS) and statistically significantly fewer events of atrial fibrillation versus ibrutinib in ...
Imbruvica®-based regimens induce lasting remissions in leukaemia trials europeanpharmaceuticalreview
May 21, 2021
Imbruvica® (ibrutinib) plus ventoclax and single-agent Imbruvica induced remissions lasting up to seven years in first-line treatment of chronic lymphocytic leukaemia.
NICE backs AstraZeneca’s Calquence for CLL pharmatimes
March 18, 2021
The UK National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s Calquence for use on the NHS to treat a common form of leukaemia.
Acute myeloid leukaemia market to reach $5.1 billion by 2029: GlobalData expresspharma
June 22, 2020
This growth will be driven by label expansions of the already successful drugs Venclexta, Tibsovo, Idhifa and Xospata, as well as by a strong late-stage pipeline.
Shilpa Medicare IBRUSHIL for treatment of leukaemia expresspharma
May 29, 2020
Earlier it had launched Lenvatinib ‘LENSHIL and Dasatinib ‘DASASHIL’ in the India market.
Venclexta/Venclyxto combo extends myeloid leukaemia survival pharmatimes
March 25, 2020
Roche has announced that its Phase III VIALE-A study, evaluating Venclexta/Venclyxto (venetoclax) in combination with azacitidine for acute myeloid leukaemia (AML), has met its dual primary endpoints.
AstraZeneca gets marketing permission for leukaemia drug in India expresspharma
March 13, 2020
AstraZeneca Pharma has received approval from India’s drug regulator to market Acalabrutinib 100mg capsules, medicine for the treatment of chronic lymphocytic leukaemia.
Repurposing leukaemia drugs may prevent melanoma metastasis europeanpharmaceuticalreview
April 25, 2019
Data from a new study shows that repurposing drugs used to treat leukaemia has promise for preventing melanoma metastasis…
Penn presents positive results for targeted leukaemia drug pharmpacpeutical-technology
April 03, 2019
Researchers from the University of Pennsylvania (Penn) Abramson Cancer Center have announced findings from the ADMIRAL trial of gilteritinib in patients with relapsed or refractory acute myeloid leukaemia (AML) with a mutation in the Fms-like tyrosine kin

Previous page 1 2 3 Next page